EntreMed (Nasdaq: EMND) has been through plenty of turbulence. In 1998, it was the subject of a breathless front page New York Times story suggesting the biotech was on the verge of curing cancer, based on promising mice studies. Those hopes (and EntreMed's share price) deflated in the coming years, when the company found itself shedding jobs and executives and struggling to survive.
But through it all, EntreMed remained EntreMed. No longer: the Rockville company's shareholders have voted to change its name to CASI Pharmaceuticals, as of June 16. The company will now trade under the ticker symbol CASI.